Ingham M - Search Results

1

Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).

Ingham M, Allred JB, Chen L, Das B, Kochupurakkal B, Gano K, George S, Attia S, Burgess MA, Seetharam M, Boikos SA, Bui N, Chen JL, Close JL, Cote GM, Thaker PH, Ivy SP, Bose S, D'Andrea A, Marino-Enriquez A, Shapiro GI, Schwartz GK. Ingham M, et al. J Clin Oncol. 2023 Sep 1;41(25):4154-4163. doi: 10.1200/JCO.23.00402. Epub 2023 Jul 19. J Clin Oncol. 2023. PMID: 37467452 Free PMC article.

2

Cell-Cycle Therapeutics Come of Age.

Ingham M, Schwartz GK. Ingham M, et al. J Clin Oncol. 2017 Sep 1;35(25):2949-2959. doi: 10.1200/JCO.2016.69.0032. Epub 2017 Jun 3. J Clin Oncol. 2017. PMID: 28580868 Free PMC article. Review.

3

Emerging Targeted and Immune-Based Therapies in Sarcoma.

Pollack SM, Ingham M, Spraker MB, Schwartz GK. Pollack SM, et al. Among authors: ingham m. J Clin Oncol. 2018 Jan 10;36(2):125-135. doi: 10.1200/JCO.2017.75.1610. Epub 2017 Dec 8. J Clin Oncol. 2018. PMID: 29220291 Review.

4

Homologous recombination repair deficiency as a therapeutic target in sarcoma.

Oza J, Doshi SD, Hao L, Musi E, Schwartz GK, Ingham M. Oza J, et al. Among authors: ingham m. Semin Oncol. 2020 Dec;47(6):380-389. doi: 10.1053/j.seminoncol.2020.10.002. Epub 2020 Oct 24. Semin Oncol. 2020. PMID: 33183763 Review.

5

Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors.

Sheikh TN, Chen X, Xu X, McGuire JT, Ingham M, Lu C, Schwartz GK. Sheikh TN, et al. Among authors: ingham m. Mol Cancer Ther. 2021 Dec;20(12):2362-2371. doi: 10.1158/1535-7163.MCT-21-0066. Epub 2021 Sep 22. Mol Cancer Ther. 2021. PMID: 34552007 Free PMC article.

6

Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma.

Doshi SD, Oza J, Remotti H, Remotti F, Moy MP, Schwartz GK, Ingham M. Doshi SD, et al. Among authors: ingham m. JCO Precis Oncol. 2021 Nov;5:1-5. doi: 10.1200/PO.20.00201. JCO Precis Oncol. 2021. PMID: 34994591 No abstract available.

7

Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents.

Ingham MA, McGuinness JE, Kalinsky K, Schwartz GK. Ingham MA, et al. JCO Precis Oncol. 2018 Nov;2:1-6. doi: 10.1200/PO.18.00131. JCO Precis Oncol. 2018. PMID: 35135137 No abstract available.

8

Novel Therapeutics in the Treatment of Uterine Sarcoma.

Bose S, Schwartz GK, Ingham M. Bose S, et al. Among authors: ingham m. Am Soc Clin Oncol Educ Book. 2022 Apr;42:900-909. doi: 10.1200/EDBK_350541. Am Soc Clin Oncol Educ Book. 2022. PMID: 35714303 Free article.

9

CDK4/6 Inhibition With Anti-PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD-1 Alone.

Bose S, Lee T, Choi S, Fazlollahi L, Rasiej MJ, Schwartz GK, Ingham M. Bose S, et al. Among authors: ingham m. JCO Precis Oncol. 2022 Jul;6:e2100550. doi: 10.1200/PO.21.00550. JCO Precis Oncol. 2022. PMID: 35820086 No abstract available.

10

A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma.

Ingham M, Lee S, Van Tine BA, Choy E, Oza J, Doshi S, Ge L, Oppelt P, Cote G, Corgiat B, Sender N, Sta Ana S, Panchalingam L, Petricoin E, Schwartz GK. Ingham M, et al. Clin Cancer Res. 2023 Mar 14;29(6):1031-1039. doi: 10.1158/1078-0432.CCR-22-3351. Clin Cancer Res. 2023. PMID: 36548343 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters